论文部分内容阅读
目的 探讨缓释型促性腺激素释放激素拟似剂醋酸亮丙瑞林治疗特发性中枢性性早熟 (ICPP)女童治疗前和治疗 6个月后的临床早熟表现的变化 ,以及血清雌二醇 (E2 )、胰岛素样生长因子Ⅰ (IGF Ⅰ )、胰岛素样生长因子结合蛋白 (IGFBP3 )浓度变化。方法 2 7例ICPP女童均接受缓释型醋酸亮丙瑞林治疗 6个月 ,每公斤体重 5 0～ 10 0 μg ,每月皮下注射 1次。于治疗前至治疗 6个月末观察身高、体重、性征、骨龄、B超子宫、卵巢的变化 ,以及血清E2 、IGF Ⅰ、IGFBP3 浓度变化。结果 接受缓释型醋酸亮丙瑞林治疗的 2 7例ICPP女童 ,治疗 6个月末与治疗前相比 ,性征消退 ,生长速度下降 ,骨龄进展缓慢 ,子宫、卵巢、E2 恢复到青春期前水平 ,而血清IGF Ⅰ和IGFBP3 水平差异无显著意义 (P >0 0 5 )。结论 用缓释型促性腺激素释放激素拟似剂治疗ICPP女童 6个月后 ,临床早熟表现明显得到控制 ,血清E2 水平明显降低。血清IGF Ⅰ和IGF BP3 水平无明显改变。
Objective To investigate the clinical preclinical changes of pregnant women with idiopathic central precocious puberty (ICPP) before and 6 months after treatment with sustained-release gonadotropin-releasing hormone mimicking leuprolide, and the changes of serum estradiol (E2), insulin - like growth factor Ⅰ (IGF Ⅰ) and insulin - like growth factor binding protein (IGFBP3) Methods Twenty-seven ICPP girls were treated with sustained-release leuprolide for 6 months, with a mean daily dose of 50 ~ 100 μg / kg and subcutaneous injection once a month. The changes of height, weight, sexual characteristics, bone age, B-uterus, ovary and serum E2, IGF Ⅰ, IGFBP3 concentrations before treatment were observed at the end of 6 months. RESULTS: Twenty-seven ICPP girls treated with sustained-release leuprolide acetate showed signs of regression, decreased growth rate, slow progression of bone age, and restoration of uterine, ovarian, and E2 levels to pre-puberty levels at the end of 6 months , While there was no significant difference in serum IGF Ⅰ and IGFBP3 levels (P> 0.05). Conclusion After 6 months’ treatment of ICPP girls with sustained-release gonadotropin-releasing hormone analogue, precocious precocious puberty is obviously controlled and the level of serum E2 is obviously decreased. Serum IGF Ⅰ and IGF BP3 levels did not change significantly.